Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
7.31
-0.23 (-3.05%)
At close: Oct 23, 2026, 4:00 PM EDT
7.40
+0.09 (1.23%)
Pre-market: Oct 26, 2026, 7:20 AM EDT
Immatics Employees
Immatics had 704 employees as of June 30, 2026. The number of employees increased by 58 or 8.98% compared to the same quarter last year. That makes Immatics the 17,432nd largest employer in the world and 2,417th in the United States.
Employees
704
Change (1Y)
58
Growth (1Y)
8.98%
Revenue / Employee
$67,678
Profits / Employee
-$335,192
Market Cap
999.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 704 | 58 | 8.98% | 704 | 0 |
| Mar 31, 2026 | 678 | 32 | 4.95% | 678 | 0 |
| Dec 31, 2025 | 711 | 29 | 4.25% | 589 | 122 |
| Sep 30, 2025 | 645 | 73 | 12.76% | 645 | 0 |
| Mar 31, 2025 | 646 | 111 | 20.75% | 646 | 0 |
| Dec 31, 2024 | 682 | 147 | 27.48% | 554 | 128 |
| Sep 30, 2024 | 572 | 139 | 32.10% | 572 | 0 |
| Jun 30, 2024 | 542 | 140 | 34.83% | 542 | 0 |
| Dec 31, 2023 | 535 | 93 | 21.04% | 432 | 103 |
| Sep 30, 2023 | 433 | 45 | 11.60% | 433 | 0 |
| Mar 31, 2023 | 402 | 29 | 7.77% | 402 | 0 |
| Dec 31, 2022 | 442 | 61 | 16.01% | 358 | 84 |
| Jun 30, 2022 | 388 | 57 | 17.22% | 388 | 0 |
| Mar 31, 2022 | 373 | 90 | 31.80% | 373 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Replimune Group | 465 |
| MoonLake Immunotherapeutics | 130 |
| Janux Therapeutics | 113 |
| Odyssey Therapeutics | 100 |
| Vor Biopharma | 76 |
| Savara | 70 |
| Seaport Therapeutics | 58 |
IMTX News
- 15 hours ago - Immatics announces updated trial data from Phase 1b study of IMA402 - TheFly
- 2 days ago - Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting - GlobeNewsWire
- 12 days ago - Immatics initiated with a Buy at Stifel - TheFly
- 2 months ago - Immatics price target lowered to $17 from $18 at Jefferies - TheFly
- 2 months ago - Immatics announces $150M offering of common stock priced at $8.69 per share - TheFly
- 2 months ago - Immatics Announces $150 Million Underwritten Offering - GlobeNewsWire
- 2 months ago - Immatics Earnings release: Q2 2026 - Filings
- 2 months ago - Immatics reports Q2 EPS (46c), consensus (48c) - TheFly